Allozyne develops technologies that improve the efficacy, safety, dosing, and other characteristics of protein-based therapeutics.
Allozyne develops and commercializes technologies that enable improvements in the efficacy, safety, dosing, and other characteristics of protein-based therapeutics, including peptides, antibodies, and vaccines. Its PEGylated IFN beta is for the treatment of multiple sclerosis. The company was founded in 2005 and is based in Seattle, Washington.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Oct 26, 2007 | Series B | $30M | 1 | — | — | Detail |
Dec 6, 2005 | Series A | $3.50M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
ARCH Venture Partners | — | Series B |